Cyclosporine (Atopica for Cats) for Feline Allergic Dermatitis: Efficacy and Safety

Bottom line

• In a masked, vehicle-controlled field study of 181 cats, Atopica for Cats (cyclosporine oral solution) produced a 65.1% reduction in mean total lesion score versus 9.2% in the control group — a statistically significant difference established in the pivotal NADA study.[1]
• A 6-month repeated-dose safety study confirmed that serious adverse effects (bone marrow changes, lymphoma) occurred only in cats receiving more than twice the approved label dose; gastrointestinal adverse effects are the most commonly observed reactions at any dose, but no significant drug accumulation occurs beyond the first week.[2]
• Key precautions: Cyclosporine is a systemic immunosuppressant and should not be used in cats with a history of malignancy, FeLV-positive or FIV-positive cats, or concurrently with other immunosuppressants; one cat in the 205-cat field study died of effusive feline infectious peritonitis.
• A pharmacokinetics study confirms nonlinear oral bioavailability across the dose range in cats; whole blood concentration 4 hours after administration correlates best with total drug exposure (R^2 = 0.896), which is the recommended monitoring window when therapeutic drug monitoring is performed.[3]

Drug facts

• Class: Calcineurin inhibitor; cyclic polypeptide
• Mechanism: Binds cyclophilin → inhibits calcineurin → blocks nuclear factor of activated T-cells (NFAT) transcription → reduced IL-2 and T-cell activation
• Route/interval: Oral solution (100 mg/mL); initial label-directed daily dosing with potential taper to alternate days or twice-weekly for long-term maintenance
• Indication: Control of feline allergic dermatitis as manifested by facial/neck excoriations, miliary dermatitis, eosinophilic plaques, and self-induced alopecia in cats at least 6 months of age and at least 3 lbs
• Approval: FDA NADA (Elanco, US); labeled New Animal Drug Application. Category: Prescription.
• Label contraindications: History of malignancy or suspected malignancy; FeLV or FIV positive cats; concurrent use with other immunosuppressants
• Label common AEs: Weight loss, anorexia, vomiting, diarrhea, hypersalivation, lethargy; 6.8% withdrawal rate (14/205 cats) in the pivotal field study; rare toxoplasma reactivation at supratherapeutic doses

A specific patient on cyclosporine for feline allergic dermatitis?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=cyclosporine-cats-allergic-dermatitis

What the evidence shows

Pivotal field study: efficacy in feline allergic dermatitis

The pivotal effectiveness data for Atopica for Cats (cyclosporine oral solution USP modified, 100 mg/mL) derive from a masked, randomized, controlled field study conducted at 24 sites across the United States and Canada, as reported in the FDA-approved label (DailyMed) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47f70173-a1d9-4156-9a7f-0f296e5dd64b). The study enrolled 217 client-owned cats with a clinical diagnosis of allergic dermatitis — encompassing miliary dermatitis, excoriations, self-induced alopecia, and eosinophilic plaques combined with non-seasonal pruritus — randomized 2:1 to Atopica or vehicle control. Evaluable data from 181 cats formed the effectiveness population.

Cats receiving Atopica for Cats achieved a mean 65.1% reduction in total lesion score; the vehicle control group showed only 9.2% reduction. The between-group difference was statistically significant. The study duration allowed for the minimum 4-to-6-week initial treatment period specified on the label.

The withdrawal rate of 6.8% (14 of 205 enrolled cats) due to adverse reactions — predominantly gastrointestinal signs and weight loss — was concentrated in the early weeks and is consistent with the known tolerability profile of cyclosporine in cats. One cat died of the effusive form of feline infectious peritonitis, a known risk in immunosuppressed patients.

Target animal safety at the label dose

Roberts et al. (2014, J Vet Pharmacol Ther (https://pubmed.ncbi.nlm.nih.gov/24134659/)) conducted a 6-month target animal safety study in 40 healthy cats receiving the labeled dose or escalating multiples (1x, 2x, 3x, or 5x) administered daily. Serious adverse effects potentially attributable to treatment — prolonged APTT, one case of bone marrow hypocellularity, and one case of lymphoma — were observed only in cats receiving doses greater than twice the approved label dose (the 3-times and 5-times groups); the 1-times dose group did not exhibit these findings. No significant drug accumulation beyond the first week was observed at any dose level. At the 1-times-label dose, the drug was safe and well tolerated throughout the 183-day study period. This study formed part of the safety data package supporting FDA approval.

Pharmacokinetics and monitoring

Kong et al. (2023, Vet Sci (https://pubmed.ncbi.nlm.nih.gov/37368785/)) characterized the absolute bioavailability of Atopica for Cats using intravenous and oral administration across a range of doses. Oral bioavailability followed a nonlinear profile: the medium oral dose (corresponding to the labeled dose range) achieved 36.98% bioavailability, substantially higher than either the lower or higher dose groups, confirming that dosing outside the labeled range produces disproportionate pharmacokinetic changes. Among candidate monitoring time points, whole blood concentration at 4 hours post-dose showed the strongest correlation with total drug exposure (R^2 = 0.896), providing practical guidance for therapeutic drug monitoring in clinical practice.

Indications and conditions managed

The labeled indications encompass the four primary presentations of feline allergic dermatitis: facial and neck excoriations, miliary dermatitis, self-induced alopecia, and eosinophilic plaques. The drug is not labeled for use in cats younger than 6 months or weighing less than 1.4 kg (approximately 3 lbs). The maintenance taper to alternate-day or twice-weekly dosing is supported by the clinical evidence for sustained disease control while reducing cumulative drug exposure.

Safety considerations: immunosuppression and infectious disease

As a systemic calcineurin inhibitor, cyclosporine substantially increases susceptibility to opportunistic infections and neoplasia. The label explicitly prohibits use in cats known or suspected to have a malignancy and in cats testing positive for FeLV or FIV. Toxoplasma gondii reactivation was identified as a risk in supratherapeutic dose safety studies; cats with potential exposure history should be considered for baseline Toxoplasma serology before initiating treatment.

How this fits clinical practice

Cyclosporine represents an established alternative to corticosteroids for managing feline allergic dermatitis — particularly in cats where long-term steroid use is undesirable (e.g., concurrent diabetes mellitus, severe mineralocorticoid effects). The 65.1% lesion score reduction from the pivotal field study provides a meaningful benchmark against which clinical response can be gauged.

The initial 4-to-6-week daily dosing period is the highest-risk window for gastrointestinal adverse effects. Feeding the drug alongside a small amount of food, per label instructions, helps mitigate hypersalivation and vomiting. Baseline and periodic monitoring for lymphocyte counts and clinical chemistry is prudent given the immunosuppressive mechanism.

Before initiating therapy, FeLV/FIV testing is required by the label contraindications. A working diagnosis of atopic skin disease should be established; cyclosporine's immunosuppressive mechanism is less appropriate for primary infectious skin conditions.

The nonlinear pharmacokinetics identified by Kong et al. underscore the importance of dosing at the label-specified amount rather than approximating from the canine Atopica dose, which is considerably different from the feline formulation.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=cyclosporine-cats-allergic-dermatitis

References

1. Atopica for Cats (cyclosporine oral solution) drug label. DailyMed. Elanco US Inc. NADA. Updated January 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47f70173-a1d9-4156-9a7f-0f296e5dd64b
2. Roberts ES, Vanlare KA, Strehlau G, Peyrou M, Roycroft LM, King S. Safety, tolerability, and pharmacokinetics of 6-month daily dosing of an oral formulation of cyclosporine (ATOPICA for cats) in cats. J Vet Pharmacol Ther. 2014;37(2):161-168. https://pubmed.ncbi.nlm.nih.gov/24134659/
3. Kong J, Yang Y, Liu Y, Cao Y, Qiu J, Sun P, Cao X. The Pharmacokinetic and Absolute Bioavailability of Cyclosporine (Atopica for Cats) in Cats. Vet Sci. 2023;10(6):399. https://pubmed.ncbi.nlm.nih.gov/37368785/

Changelog

• 2026-06-08: First published.

Related reads

• Gabapentin for Pre-Visit Feline Anxiety: Evidence and Clinical Use
• Mirtazapine Transdermal Ointment (Mirataz) for Feline Weight Loss
• Cyclosporine Canine Atopic Dermatitis